| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-07-0760 |
| P698 | PubMed publication ID | 18094426 |
| P50 | author | Gordon B. Mills | Q28086262 |
| Ana Maria Gonzalez-Angulo | Q107718318 | ||
| Bryan T. Hennessy | Q117214243 | ||
| P2093 | author name string | Yiling Lu | |
| Murali Ravoori | |||
| Vikas Kundra | |||
| Robert Birch | |||
| Mark S Carey | |||
| Shuangxing Yu | |||
| I Craig Henderson | |||
| Enrique Poradosu | |||
| Hassan Hall | |||
| Qianghua Yu | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| P304 | page(s) | 7421-7431 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Pharmacodynamic markers of perifosine efficacy | |
| P478 | volume | 13 |
| Q35049524 | A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers |
| Q36944047 | A novel AKT3 mutation in melanoma tumours and cell lines |
| Q51023478 | A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. |
| Q36815701 | Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS |
| Q34118999 | Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression |
| Q36578468 | An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays |
| Q37187915 | An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer |
| Q38058582 | Anticancer mechanisms and clinical application of alkylphospholipids |
| Q37736908 | Are we on the brink of nonsurgical treatment for ameloblastoma? |
| Q42478581 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells |
| Q37168778 | Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer |
| Q24315876 | CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cells |
| Q39739265 | Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma |
| Q28751743 | Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics |
| Q39325158 | Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner |
| Q39674037 | Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo |
| Q42516513 | Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer |
| Q89616229 | Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma |
| Q37270455 | Drug discovery approaches targeting the PI3K/Akt pathway in cancer |
| Q31056323 | Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells |
| Q38474631 | Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine |
| Q36260570 | Epithelial to mesenchymal transition is associated with rapamycin resistance |
| Q30494709 | Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy |
| Q35206302 | Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer |
| Q42140840 | Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma |
| Q37373348 | Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin |
| Q52607328 | Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas |
| Q39631346 | In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines |
| Q39162763 | Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells. |
| Q39712898 | Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers |
| Q42723115 | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma |
| Q24633201 | Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer |
| Q43122600 | Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. |
| Q42191925 | Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach |
| Q35894198 | MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition |
| Q44577463 | Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. |
| Q38023101 | Merlin: The wizard requires protein stability to function as a tumor suppressor |
| Q37576912 | Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells |
| Q54500736 | Molecular alterations in AKT and its protein activation in human lung carcinomas |
| Q33722849 | Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor |
| Q39089022 | NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription |
| Q33882138 | Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain |
| Q37727180 | PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes |
| Q35838565 | PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors |
| Q39270813 | Perifosine Induces Cell Apoptosis in Human Osteosarcoma Cells: New Implication for Osteosarcoma Therapy? |
| Q39202496 | Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts |
| Q36355806 | Perifosine as a potential novel anti-telomerase therapy |
| Q38068572 | Perifosine in renal cell carcinoma |
| Q24645466 | Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy |
| Q37082453 | Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer |
| Q37393008 | Perifosine: update on a novel Akt inhibitor. |
| Q34485296 | Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer |
| Q82124476 | Pharmacoproteomics and toxicoproteomics: The field of dreams |
| Q35606261 | Phosphatidylinositol-3-kinase as a therapeutic target in melanoma |
| Q54286593 | Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model. |
| Q49180082 | Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. |
| Q36957198 | Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance |
| Q35584641 | Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer |
| Q37656270 | Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. |
| Q37625678 | Proteome and Acetylome Analysis Identifies Novel Pathways and Targets Regulated by Perifosine in Neuroblastoma |
| Q34048140 | Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer |
| Q36030339 | Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence |
| Q47146817 | Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients |
| Q85037930 | Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer |
| Q42378446 | Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes |
| Q34127953 | Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. |
| Q29617685 | Targeting PI3K signalling in cancer: opportunities, challenges and limitations |
| Q35911227 | The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. |
| Q50040409 | The Integrated Genomic Landscape of Thymic Epithelial Tumors |
| Q54423334 | The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. |
| Q35185640 | The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities |
| Q35566231 | Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers |
| Q38545364 | Variable slope normalization of reverse phase protein arrays |
| Q36126413 | Zinc and Cancer: Implications for LIV-1 in Breast Cancer |
| Q30541608 | c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer |
| Q30371561 | p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. |
Search more.